Mark J. Millan

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

Mark J. Millan, Alain P. Gobert, F. Lejeune et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 512 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment

Mark J. Millan, K.C.F. Fone, Thomas Steckler et al. · European Neuropsychopharmacology · 2014 · 345 citations · Full text

Medicine, Neuroscience, Psychiatry +17

Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat

Alain P. Gobert, Jean‐Michel Rivet, Adrian Newman‐Tancredi et al. · Synapse · 2000 · 336 citations

Medicine, Neuroscience, Pharmacology +17

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo

Mark J. Millan, Anne Dekeyne, Alain P. Gobert · Neuropharmacology · 1998 · 283 citations

Life Sciences, Neuroscience, Pharmacology +12

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

Mark J. Millan, Mauricette Brocco, Alain P. Gobert et al. · Psychopharmacology · 2004 · 245 citations

Medicine, Pharmacology, Psychiatry +16